نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 250mg equivalent to 200 mg indinavir;  ;   - capsule - 200 mg - active: indinavir sulfate 250mg equivalent to 200 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint blue sb-6018 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dacarbazine 200mg;  ;   - powder for injection - 200 mg - active: dacarbazine 200mg     excipient: citric acid monohydrate mannitol - chemotherapy of metastatic malignant melanoma and various sarcomas. in other cancers, the available evidence shows dacarbazine to be ineffective or less effective than established regimens.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - emtricitabine 200mg;  ;  ;   - capsule - 200 mg - active: emtricitabine 200mg       excipient: crospovidone gelatin indigo carmine magnesium stearate microcrystalline cellulose povidone titanium dioxide - emtriva is indicated for the treatment of hiv in combination with other antiretroviral agents in adults and paediatric patients 12 years of age and older, weighing more than 33 kg. evidence to support this claim is based on surrogate markers (plasma hiv rna and cd4 count) in antiretroviral na?ve individuals and in antiretroviral experienced individuals with virological suppression.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg;   - powder for injection - 2000 mg - active: cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - entacapone 200mg;   - film coated tablet - 200 mg - active: entacapone 200mg   excipient: hydrogenated vegetable oil hyprolose magnesium stearate mannitol microcrystalline cellulose opadry orange water - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilized on those combinations.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 200mg; sodium valproate 200mg; sodium valproate 200mg - modified release tablet - 200 mg - active: sodium valproate 200mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray violet k-1-4613 polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 200mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 200mg excipient: calcium silicate magnesium stearate povidone purified talc violet enteric coat excipient blend violet sub-coat excipient blend - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 200mg - capsule - 200 mg - active: fluconazole 200mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 200mg - capsule - 200 mg - active: fluconazole 200mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide erythrosine ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole is indicated for the treatment of the following conditions: 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. ozole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseninated candidasis and other forms of invasive candidal infection, including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytoxic chemotherapy, radiotherapy or bone marrow transplant. 6. ozole 50 mg and 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine;  ;   - powder for injection - 200 mg - active: gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine     excipient: mannitol nitrogen sodium acetate as sodium acetate trihydrate sodium hydroxide - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - labetalol hydrochloride 200mg;  ; labetalol hydrochloride 200mg - film coated tablet - 200 mg - active: labetalol hydrochloride 200mg   excipient: carnauba wax lactose monohydrate magnesium stearate maize starch opaspray orange k-1r-2433 pregelatinised maize starch sodium starch glycolate active: labetalol hydrochloride 200mg excipient: carnauba wax diethyl phthalate ethanol hypromellose e-15 lactose monohydrate magnesium stearate maize starch opaspray orange k-1r-2433 pregelatinised maize starch purified water sodium starch glycolate